Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis
作者
Yuan, T;Zhang, F;Yao, QM;Liu, YX;Zhu, XJ;Wang, X
作者单位
[Yuan, Ting; Zhang, Feng; Yao, Qing-min; Liu, Yan-xia; Zhu, Xiao-juan; Wang, Xin] Shandong Univ, Shandong Prov Hosp, Dept Hematol, Jinan, Shandong, Peoples R China.
摘要
Background;-;Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain.;-;Methods;-;We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Library and Emabase from inception to July 29, 2016. The primary outcome was the overall response rate including the complete response rate and the partial response rate. The secondary outcomes were the proportions of patients in each group experiencing the adverse events including the neutropathy, fatigue, diarrhea, nausea and neutropenia.;-;Findings;-;After final screening, six trials were considered eligible for analysis. The results showed that the overall response rate of biweekly schedule was higher than that of weekly schedule in indolent lymphoma (OR 1.691; 95% CI 1.02-2.80). Furthermore, there were no significant differences between the two schedules of bortezomib for the main adverse events.;-;Interpretation;-;The biweekly schedule of bortezomib was more effective than the weekly schedule in indolent lymphoma, with similar proportion of toxicities.
关键词
REFRACTORY FOLLICULAR LYMPHOMA; MANTLE CELL LYMPHOMA; PROTEASOME INHIBITOR BORTEZOMIB; NATIONAL-CANCER-INSTITUTE; CLINICAL-TRIALS GROUP; PHASE-II; RITUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE
基本信息
